$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

$csbr Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000162828024040312 Filed on September 13, 2024

Income Statement

Concept	2024 Q3
Revenue	$14.06M
YoY Change	11.94%
Cost Of Revenue	$7.072M
YoY Change	-7.96%
Gross Profit	$6.989M
YoY Change	43.31%
Gross Profit Margin	49.7%
Selling, General & Admin	$4.206M
YoY Change	-9.28%
% of Gross Profit	60.18%
Research & Development	$1.454M
YoY Change	-47.94%
% of Gross Profit	20.8%
Depreciation & Amortization	$449.0K
YoY Change	0.9%
% of Gross Profit	6.42%
Operating Expenses	$5.660M
YoY Change	-23.81%
Operating Profit	$1.329M
YoY Change	-152.08%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$5.000K
YoY Change	-64.29%
Pretax Income	$1.334M
YoY Change	-152.56%
Income Tax	$21.00K
% Of Pretax Income	1.57%
Net Earnings	$1.313M
YoY Change	-150.5%
Net Earnings / Revenue	9.34%
Basic Earnings Per Share	$0.10
Diluted Earnings Per Share	$0.09
COMMON SHARES
Basic Shares Outstanding	13.59M shares
Diluted Shares Outstanding	14.04M shares

Balance Sheet

Concept	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.892M
YoY Change	-40.6%
Cash & Equivalents	$2.892M
Short-Term Investments
Other Short-Term Assets	$1.254M
YoY Change	13.48%
Inventory
Prepaid Expenses
Receivables	$9.032M
Other Receivables	$0.00
Total Short-Term Assets	$13.18M
YoY Change	-11.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.24M
YoY Change	-22.33%
Goodwill	$335.0K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$185.0K
YoY Change	0.54%
Total Long-Term Assets	$11.76M
YoY Change	-21.55%
TOTAL ASSETS
Total Short-Term Assets	$13.18M
Total Long-Term Assets	$11.76M
Total Assets	$24.93M
YoY Change	-16.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.235M
YoY Change	-9.1%
Accrued Expenses	$2.097M
YoY Change	0.29%
Deferred Revenue	$10.31M
YoY Change	-7.45%
Short-Term Debt	$0.00
YoY Change
Long-Term Debt Due	$151.0K
YoY Change
Total Short-Term Liabilities	$19.16M
YoY Change	-5.98%
LONG-TERM LIABILITIES
Long-Term Debt	$182.0K
YoY Change
Other Long-Term Liabilities	$363.0K
YoY Change	-29.38%
Total Long-Term Liabilities	$363.0K
YoY Change	-29.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.16M
Total Long-Term Liabilities	$363.0K
Total Liabilities	$25.27M
YoY Change	-9.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$83.30M
YoY Change	4.26%
Common Stock	$83.66M
YoY Change	1.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$332.0K
YoY Change
Total Liabilities & Shareholders Equity	$24.93M
YoY Change	-16.63%

Cashflow Statement

Concept	2024 Q3
OPERATING ACTIVITIES
Net Income	$1.313M
YoY Change	-150.5%
Depreciation, Depletion And Amortization	$449.0K
YoY Change	0.9%
Cash From Operating Activities	$311.0K
YoY Change	-107.78%
INVESTING ACTIVITIES
Capital Expenditures	$0.00
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$37.00K
YoY Change	-93.73%
NET CHANGE
Cash From Operating Activities	$311.0K
Cash From Investing Activities	$0.00
Cash From Financing Activities	-$37.00K
Net Change In Cash	$274.0K
YoY Change	-105.22%
FREE CASH FLOW
Cash From Operating Activities	$311.0K
Capital Expenditures	$0.00
Free Cash Flow	$311.0K
YoY Change	-106.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14061000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12561000	usd
CY2023Q3	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2024#ServiceMember
CY2024Q3	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2024#ServiceMember
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7072000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7684000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1454000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2793000	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1679000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1696000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2527000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2940000	usd
CY2024Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	12732000	usd
CY2023Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	15113000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1329000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2552000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	14000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1334000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2538000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	28000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	1313000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13506782	shares
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-1903000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	258000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4636000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2566000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1903000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	1313000	usd
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	258000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	423000	usd
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	449000	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	445000	usd
CY2024Q3	csbr	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	289000	usd
CY2023Q3	csbr	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	270000	usd
CY2024Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-71000	usd
CY2023Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	162000	usd
CY2024Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-565000	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1099000	usd
CY2024Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-241000	usd
CY2023Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-223000	usd
CY2024Q3	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
CY2023Q3	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	169000	usd
CY2024Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-565000	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	424000	usd
CY2024Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-63000	usd
CY2023Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-178000	usd
CY2023Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	668000	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-668000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6100000	usd
CY2024Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9032000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	1313000	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2024Q3	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2566000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.10
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13593766	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13506782	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14042379	shares
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-332000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	423000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	12000	usd
CY2023Q3	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	602000	usd
CY2024Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-323000	usd
CY2023Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-292000	usd
CY2024Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1782000	usd
CY2023Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1634000	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	311000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3991000	usd
CY2024Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2024Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12000	usd
CY2024Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	37000	usd
CY2023Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2024Q3	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023Q3	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	602000	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-37000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-590000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	274000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5249000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2618000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10118000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2892000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4869000	usd
CY2024Q3	csbr	Number Of Operating Subsidiaries NumberOfOperatingSubsidiaries	4	subsidiary
CY2024Q3	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-7300000	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	311000	usd
CY2024Q3	csbr	Working Capital Deficit WorkingCapitalDeficit	6000000.0	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-83300000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	1313000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13593766	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13506782	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.10
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1313000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2566000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13593766	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13506782	shares
CY2024Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	448613	shares
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14042379	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13506782	shares
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1131624	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1766752	shares
CY2024Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2023Q3	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2024Q3	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2024Q3	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	0	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	28000	usd
CY2024Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	4722000	usd
CY2024Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	4886000	usd
CY2023Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	3843000	usd
CY2024Q3	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	5540000	usd
CY2024Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	5941000	usd
CY2023Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	4993000	usd
CY2024Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	10262000	usd
CY2024Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	10827000	usd
CY2023Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	8836000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1230000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1301000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	825000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9526000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8011000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1301000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	0	usd
CY2024Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-71000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1230000	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	10312000	usd
CY2024Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12094000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12776000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14061000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12561000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16112000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16112000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10840000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10391000	usd
CY2024Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	5272000	usd
CY2024Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	5721000	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	449000	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	445000	usd
CY2024Q3	csbr	Depreciation And Amortization Excluding Finance Leases DepreciationAndAmortizationExcludingFinanceLeases	412000	usd
CY2023Q3	csbr	Depreciation And Amortization Excluding Finance Leases DepreciationAndAmortizationExcludingFinanceLeases	409000	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	1000000.0	usd
CY2024Q3	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	1000000.0	usd
CY2024Q3	csbr	Finance Lease Depreciation And Amortization Expenses FinanceLeaseDepreciationAndAmortizationExpenses	37000	usd
CY2023Q3	csbr	Finance Lease Depreciation And Amortization Expenses FinanceLeaseDepreciationAndAmortizationExpenses	36000	usd
CY2024Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M9D
CY2024Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	333000	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	370000	usd
CY2024Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	151000	usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	150000	usd
CY2024Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	182000	usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	220000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	120000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	140000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	80000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	6000	usd
CY2024Q3	csbr	Finance Lease Liability To Be Paid Due After Year Three FinanceLeaseLiabilityToBePaidDueAfterYearThree	0	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	346000	usd
CY2024Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	13000	usd
CY2024Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	333000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	258000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	423000	usd
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0448
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0395
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6272
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6283
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.02
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.72
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1919497	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.04
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y2M12D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2172000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.90
CY2024Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y9M18D
CY2024Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2024Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	500	shares
CY2024Q3	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	6.11
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2024Q3	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice	0
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1919997	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.04
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2125000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1919997	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.04
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2125000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1555579	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.74
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y1M6D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2125000	usd
CY2023Q1	srt	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	5000000	usd
CY2024Q3	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	120333	shares
CY2024Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	5.73
CY2024Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	708000	usd
CY2024Q3	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	4300000	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	454000	usd
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	454000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5963000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6252000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1369000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1337000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5738000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6093000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y5M26D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0588
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y5M19D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0587
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2180000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2950000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2916000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2867000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2392000	usd
CY2024Q3	csbr	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	0	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13305000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6198000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	7107000	usd
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	429000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	416000	usd
CY2024Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	37000	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	36000	usd
CY2024Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3000	usd
CY2023Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4000	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	469000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	456000	usd
CY2024Q3	us-gaap	Royalty Expense RoyaltyExpense	81000	usd
CY2023Q3	us-gaap	Royalty Expense RoyaltyExpense	73000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-040312-index-headers.html	Edgar Link	pending
0001628280-24-040312-index.html	Edgar Link	pending
0001628280-24-040312.txt	Edgar Link	pending
0001628280-24-040312-xbrl.zip	Edgar Link	pending
csbr-20240731.htm	Edgar Link	pending
csbr-20240731.xsd	Edgar Link	pending
csbrq1731202410-qex311.htm	Edgar Link	pending
csbrq1731202410-qex312.htm	Edgar Link	pending
csbrq1731202410-qex321.htm	Edgar Link	pending
csbr-20240731_def.xml	Edgar Link	unprocessable
csbr-20240731_lab.xml	Edgar Link	unprocessable
csbr-20240731_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
csbr-20240731_pre.xml	Edgar Link	unprocessable
csbr-20240731_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

2024 Q3 Form 10-Q Financial Statement

#000162828024040312 Filed on September 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR CHAMPIONS ONCOLOGY, INC. Stock $csbr

2024 Q3 Form 10-Q Financial Statement

#000162828024040312 Filed on September 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr